Document 0049
 DOCN  M9470049
 TI    Birth outcomes following zidovudine therapy in pregnant women.
 DT    9409
 SO    MMWR Morb Mortal Wkly Rep. 1994 Jun 10;43(22):409, 415-6. Unique
       Identifier : AIDSLINE MED/94254774
 AB    Approximately 100,000 childbearing-aged women in the United States are
       infected with human immunodeficiency virus (HIV), and an estimated 7000
       infants are born to HIV-positive mothers each year. In the United
       States, the rate of perinatal transmission of HIV among mothers who do
       not receive antiretroviral therapy is 15%-30%. Results from a recent
       multicenter randomized double-blind clinical trial suggest that
       treatment of HIV-positive mothers and their infants with zidovudine
       (ZDV) may substantially reduce the risk for perinatal HIV transmission.
       However, any potential risk for adverse outcomes associated with use of
       antiretrovirals during pregnancy should be considered. This report
       summarizes data from the Antiretroviral Pregnancy Registry regarding use
       of ZDV and the occurrence of structural birth defects reported for
       pregnancies registered during January 1989-December 1993.
 DE    *Abnormalities, Drug-Induced  Female  Human  HIV Infections/*DRUG
       THERAPY/TRANSMISSION  Infant, Newborn  Pregnancy  Pregnancy
       Complications, Infectious/*DRUG THERAPY  Pregnancy Outcome  *Prenatal
       Exposure Delayed Effects  Registries  Zidovudine/*ADVERSE
       EFFECTS/THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).